BRPI0607817B8 - compostos macrocíclicos e seu processo de preparação - Google Patents

compostos macrocíclicos e seu processo de preparação

Info

Publication number
BRPI0607817B8
BRPI0607817B8 BRPI0607817A BRPI0607817A BRPI0607817B8 BR PI0607817 B8 BRPI0607817 B8 BR PI0607817B8 BR PI0607817 A BRPI0607817 A BR PI0607817A BR PI0607817 A BRPI0607817 A BR PI0607817A BR PI0607817 B8 BRPI0607817 B8 BR PI0607817B8
Authority
BR
Brazil
Prior art keywords
formula
preparation process
macrocyclic compounds
macrocyclic
compounds
Prior art date
Application number
BRPI0607817A
Other languages
English (en)
Inventor
Hossain Azad
Alan Busacca Carl
Hugh Senanayake Chris
Gallou Fabrice
Liu Jianxiu
K Yee Nathan
Haddad Nizar
R Kapadia Suresh
Wei Xudong
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0607817A2 publication Critical patent/BRPI0607817A2/pt
Publication of BRPI0607817B1 publication Critical patent/BRPI0607817B1/pt
Publication of BRPI0607817B8 publication Critical patent/BRPI0607817B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

processo para a preparação de compostos macrocíclicos. a presente invenção refere-se a um processo para preparar um composto macrocíclico de fórmula (i) onde um composto macrocíclico hidroxil-substituído de fórmula (3) é reagido com um composto sulfonil-substituído de fórmula quin: os compostos de fórmula (i) são agentes ativos potentes para o tratamento de infecção pelo vírus da hepatite o (hcv).
BRPI0607817A 2005-03-08 2006-03-06 compostos macrocíclicos e seu processo de preparação BRPI0607817B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65969605P 2005-03-08 2005-03-08
PCT/US2006/007954 WO2006096652A2 (en) 2005-03-08 2006-03-06 Process for preparing macrocyclic compounds

Publications (3)

Publication Number Publication Date
BRPI0607817A2 BRPI0607817A2 (pt) 2009-10-06
BRPI0607817B1 BRPI0607817B1 (pt) 2019-11-26
BRPI0607817B8 true BRPI0607817B8 (pt) 2021-05-25

Family

ID=36570780

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607817A BRPI0607817B8 (pt) 2005-03-08 2006-03-06 compostos macrocíclicos e seu processo de preparação

Country Status (17)

Country Link
US (2) US7608614B2 (pt)
EP (2) EP1863833B1 (pt)
JP (2) JP5667745B2 (pt)
KR (2) KR20140059308A (pt)
CN (2) CN103172697A (pt)
AU (1) AU2006220708B9 (pt)
BR (1) BRPI0607817B8 (pt)
CA (1) CA2600367C (pt)
DK (1) DK1863833T3 (pt)
ES (1) ES2439732T3 (pt)
IL (2) IL185779A (pt)
MX (1) MX2007010879A (pt)
NZ (1) NZ562167A (pt)
PL (1) PL1863833T3 (pt)
RU (2) RU2456296C2 (pt)
WO (1) WO2006096652A2 (pt)
ZA (1) ZA200706560B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
CA2568008C (en) * 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
CN101415705B (zh) 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2374812B1 (en) 2006-07-13 2015-04-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
EP2185524A1 (en) 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
MX2010006736A (es) 2007-12-21 2010-10-15 Avila Therapeutics Inc Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006738A (es) 2007-12-21 2010-10-15 Avila Therapeutics Inc Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
MX2010011306A (es) 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
WO2010001619A1 (ja) * 2008-07-04 2010-01-07 積水メディカル株式会社 免疫学的測定における感度増強方法又はヘモグロビンの影響回避方法
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK2364309T3 (en) 2008-12-10 2015-01-12 Achillion Pharmaceuticals Inc NEW 4-AMINO-4-OXOBUTANOYLPEPTIDER as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8633320B2 (en) 2009-05-05 2014-01-21 Boehringer Ingelheim International Gmbh Process for preparing bromo-substituted quinolines
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2903988A1 (en) 2012-10-08 2015-08-12 AbbVie Inc. Compounds useful for making hcv protease inhibitors
LT2909205T (lt) 2012-10-19 2016-12-27 Bristol-Myers Squibb Company 9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
KR20160005334A (ko) 2013-03-14 2016-01-14 아칠리온 파르마세우티칼스 인코포레이티드 소바프레비르 제조 방법
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
US9227952B2 (en) 2013-03-15 2016-01-05 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
DE69819501T2 (de) 1997-06-27 2004-09-23 Ciba Speciality Chemicals Holding Inc. Ruthenium und osmiumcarbenkatalysatoren
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
ES2290161T3 (es) * 2000-08-09 2008-02-16 F. Hoffmann-La Roche Ag Derivados de quinolina.
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
WO2004072243A2 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
JP4231524B2 (ja) * 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
EP1615949A1 (en) 2003-04-10 2006-01-18 Boehringer Ingelheim International GmbH Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction
US7173004B2 (en) 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
KR101115294B1 (ko) 2003-05-21 2012-04-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 억제제 화합물
EA200600498A1 (ru) 2003-09-22 2006-10-27 Бёрингер Ингельхайм Интернациональ Гмбх Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
AP2287A (en) * 2003-10-14 2011-10-31 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
BRPI0508867A (pt) 2004-03-15 2007-09-04 Boehringer Ingelheim Int processo para a preparação de compostos macrocìclicos
AU2005228894B9 (en) * 2004-03-30 2011-10-13 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
CA2568008C (en) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
DE102004033312A1 (de) 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
EP1794178A1 (en) 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic hcv protease inhibitors
EP1794179A1 (en) 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid

Also Published As

Publication number Publication date
RU2007136964A (ru) 2009-04-20
MX2007010879A (es) 2007-11-23
CN103172697A (zh) 2013-06-26
RU2012113243A (ru) 2013-10-10
WO2006096652A2 (en) 2006-09-14
RU2456296C2 (ru) 2012-07-20
AU2006220708B2 (en) 2012-09-27
NZ562167A (en) 2011-01-28
US8222369B2 (en) 2012-07-17
CA2600367C (en) 2014-08-12
EP1863833B1 (en) 2013-09-18
BRPI0607817B1 (pt) 2019-11-26
EP2332963A3 (en) 2011-11-16
CN101160317A (zh) 2008-04-09
DK1863833T3 (da) 2013-12-02
WO2006096652A3 (en) 2006-11-23
KR20070117664A (ko) 2007-12-12
CN101160317B (zh) 2013-03-27
EP2332963A2 (en) 2011-06-15
KR20140059308A (ko) 2014-05-15
BRPI0607817A2 (pt) 2009-10-06
US20060205638A1 (en) 2006-09-14
JP5667745B2 (ja) 2015-02-12
IL228977A (en) 2015-11-30
IL185779A (en) 2014-02-27
IL185779A0 (en) 2008-01-06
ZA200706560B (en) 2008-09-25
US7608614B2 (en) 2009-10-27
AU2006220708B9 (en) 2013-01-17
EP1863833A2 (en) 2007-12-12
IL228977A0 (en) 2013-12-31
JP2012255030A (ja) 2012-12-27
US20090326194A1 (en) 2009-12-31
PL1863833T3 (pl) 2014-03-31
ES2439732T3 (es) 2014-01-24
JP2008533014A (ja) 2008-08-21
CA2600367A1 (en) 2006-09-14
KR101514953B1 (ko) 2015-04-24
AU2006220708A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
BRPI0607817B8 (pt) compostos macrocíclicos e seu processo de preparação
CY1119988T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
BRPI0612957B8 (pt) composto, processos de preparação de compostos, composição farmacêutica e uso de um composto
NO20092399L (no) Kjemiske forbindelser
EA201101492A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
BR0315781A (pt) Composição para tratamento de infecção causada por vìrus flaviviridae
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
DE602005019700D1 (de) E, die sich für die behandlung von hepatitis-c-virusinfektionen eignen
NZ595000A (en) Imidazo[4,5-c]pyridine derivative for treating viral infections
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
ATE510846T1 (de) Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden
DE602007008616D1 (de) Verfahren zur herstellung von 4'-azidocytidinderivaten
AR083052A1 (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
BRPI0612104A8 (pt) composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
WO2008046860A3 (en) Bioavailable combinations for hcv treatment
WO2007038425A3 (en) Anti-viral compouinds
BRPI0516994A (pt) processo para preparação de pirazóis
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv
BRPI0516704A (pt) composto, processo para a preparação de um composto, processo para produzir uma composição farmacêutica, composição farmacêutica, uso de um composto e uso de uma composição farmacêutica
BR0112748A (pt) Processo para preparação de azaciclo alcanoil aminotiazóis
BRPI0412826A (pt) n-[3-(3-substituìdo-pirazolo[1,5-a]pirimidin-7-il)fenil]-s ulfonamidas e compositions e métodos relacionados a ele

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.1 NA RPI NO 2510 DE 12/02/2019 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2661 DE 04-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.